Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revlimid Multiple Myeloma Trial Paused Due to Blood Clots

This article was originally published in The Pink Sheet Daily

Executive Summary

Celgene asserts that the Mayo Clinic study will resume within weeks, after the trial design is changed to require patients to receive aspirin prior to combo therapy of Revlimid/dexamethasone.
Advertisement

Related Content

Celgene’s Revlimid In Multiple Myeloma Reviewed At ASCO For Risk Of Thrombosis
Celgene’s Revlimid In Multiple Myeloma Reviewed At ASCO For Risk Of Thrombosis
Revlimid Approved With Safeguards Against Fetal Exposure
Revlimid Approved With Safeguards Against Fetal Exposure
Celgene Revlimid PDUFA Date Extended to January
Celgene Revlimid PDUFA Date Extended to January
Celgene’s Revlimid Phase II Data Sufficient For Full Approval In MDS
Celgene’s Revlimid Phase II Data Sufficient For Full Approval In MDS

Topics

Advertisement
UsernamePublicRestriction

Register

PS062966

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel